Treatment and Prognosis of Patients With Chronic HBV Infection
NCT ID: NCT05392387
Last Updated: 2022-05-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2021-10-25
2026-10-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Study on Clinical Outcome and Treatment Optimization of Chronic Hepatitis B Patients With Hypoviremia
NCT05357183
The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia
NCT05357235
Real-world Study Optimizing Nucleotide-analogues
NCT05937178
Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B
NCT04896255
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
NCT06829329
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
peg-IFN-alpha alone
Patients with chronic HBV infection only treated with peg-IFN-alpha
Standard antiviral therapy
pegylated interferon or/and nucleos(t)ide analogues
nucleos(t)ide analogues alone
Patients with chronic HBV infection only treated with nucleos(t)ide analogues
Standard antiviral therapy
pegylated interferon or/and nucleos(t)ide analogues
combination
Patients with chronic HBV infection treated with nucleos(t)ide analogues and peg-IFN-alpha
Standard antiviral therapy
pegylated interferon or/and nucleos(t)ide analogues
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard antiviral therapy
pegylated interferon or/and nucleos(t)ide analogues
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
79 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yan Huang, MD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan Huang
Role: STUDY_DIRECTOR
Xiangya Hospital of Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Infectious Disease, Xiangya Hospital, Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Xiangya HBV project
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.